Frontline Asciminib Combination in Chronic Phase CML

NCT03906292 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Imatinib
DRUG: Nilotinib 300 mg
DRUG: Dasatinib
DRUG: Asciminib

Sponsor

University of Jena

Collaborators

[object Object]
[object Object]